BR112017021767A2 - sistema e método para triagem de alta produtividade de células cancerosas - Google Patents

sistema e método para triagem de alta produtividade de células cancerosas

Info

Publication number
BR112017021767A2
BR112017021767A2 BR112017021767A BR112017021767A BR112017021767A2 BR 112017021767 A2 BR112017021767 A2 BR 112017021767A2 BR 112017021767 A BR112017021767 A BR 112017021767A BR 112017021767 A BR112017021767 A BR 112017021767A BR 112017021767 A2 BR112017021767 A2 BR 112017021767A2
Authority
BR
Brazil
Prior art keywords
analyte
cell
indicative
measurable effect
high throughput
Prior art date
Application number
BR112017021767A
Other languages
English (en)
Inventor
Eyal Ballan
Original Assignee
Cannabics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cannabics Pharmaceuticals Inc filed Critical Cannabics Pharmaceuticals Inc
Publication of BR112017021767A2 publication Critical patent/BR112017021767A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5085—Supracellular entities, e.g. tissue, organisms of invertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/948—Sedatives, e.g. cannabinoids, barbiturates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

método para triagem de alta produtividade (hts) para identificar um analito com um efeito mensurável em células. o método supracitado compreende etapas de: (a) fornecer uma matriz que compreende uma pluralidade de amostras de célula; (b) fornecer pelo menos um analito a ser testado; (c) colocar as ditas amostras de célula em contato com o dito analito; e (d) detectar um sinal indicativo do dito efeito mensurável em células, em que a alteração do dito sinal ao longo do tempo medido na dita amostra de célula em relação a uma amostra de controle é indicativa do dito efeito mensurável do dito analito na dita amostra de célula. a presente invenção revela adicionalmente meios e métodos para identificar um analito selecionado a partir do grupo que consiste em: extrato de cannabis ou uma fração do mesmo, constituinte do tipo canabinoide, constituinte do tipo não canabinoide e quaisquer combinações dos mesmos. o analito é indicativo de atividade citotóxica ou antiproliferativa ou antimitótica ou inibitória de crescimento celular in vitro.
BR112017021767A 2015-05-27 2016-05-04 sistema e método para triagem de alta produtividade de células cancerosas BR112017021767A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562166716P 2015-05-27 2015-05-27
PCT/IL2016/050471 WO2016189525A1 (en) 2015-05-27 2016-05-04 System and method for high throughput screening of cancer cells

Publications (1)

Publication Number Publication Date
BR112017021767A2 true BR112017021767A2 (pt) 2018-07-10

Family

ID=57392961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017021767A BR112017021767A2 (pt) 2015-05-27 2016-05-04 sistema e método para triagem de alta produtividade de células cancerosas

Country Status (11)

Country Link
US (1) US20180074045A1 (pt)
EP (2) EP3954992A1 (pt)
JP (3) JP2018517428A (pt)
CN (1) CN108027372A (pt)
AU (1) AU2016268526B2 (pt)
BR (1) BR112017021767A2 (pt)
CA (1) CA2983557A1 (pt)
HK (1) HK1253861A1 (pt)
IL (1) IL254571B (pt)
MX (1) MX2017013035A (pt)
WO (1) WO2016189525A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164824A1 (en) 2012-05-03 2013-11-07 Magdent Ltd. Bone enhancement device and method
WO2016157192A1 (en) 2015-04-01 2016-10-06 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Erodium crassifolium l'her plant extracts and uses thereof
CN110799186A (zh) 2017-03-05 2020-02-14 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 治疗炎性疾病的组合物和方法
CA3074819A1 (en) * 2017-09-04 2019-03-07 Cannabics Pharmaceuticals Inc. Method for sensitivity testing of cannabinoids on patient-derived tumor biopsies and ctcs
WO2020010262A1 (en) * 2018-07-06 2020-01-09 University Of Washington High throughput drug screening of cancer stem cells
CN108866190B (zh) * 2018-07-12 2022-01-28 吉林大学 一种卵巢恶性肿瘤易感性预测试剂盒及系统
CN108841959B (zh) * 2018-07-12 2022-03-01 吉林大学 一种口腔及头颈部恶性肿瘤易感性预测试剂盒及系统
CN109298169B (zh) * 2018-09-21 2022-04-15 中国农业科学院兰州畜牧与兽药研究所 抗奶牛子宫内膜炎药物的筛选方法、细胞模型及用途
CN109642258B (zh) * 2018-10-17 2020-06-09 上海允英医疗科技有限公司 一种肿瘤预后预测的方法和系统
CA3124675A1 (en) * 2018-12-21 2020-06-25 Thsee, Llc Method for optimization of cannabis dosage and mixture of active cannabinoids
CN112162042B (zh) * 2020-09-14 2022-04-26 首都医科大学附属北京朝阳医院 超高效液相色谱串联质谱测定血浆中amg510浓度的方法
CN112285082A (zh) * 2020-10-28 2021-01-29 上海睿钰生物科技有限公司 一种基于细胞直径评价细胞杀伤效力的方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005061707A1 (ja) * 2003-12-24 2007-07-12 協和醗酵工業株式会社 癌細胞のＥｇ５阻害剤に対する感受性を判定する方法
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
FR2918073B1 (fr) 2007-06-27 2012-10-19 Univ Paris Curie Cellules fixatrices de cellules tumorales.
ATE493977T1 (de) * 2007-10-02 2011-01-15 Vivacell Biotechnology Espana S L Zusammensetzung mit nicht-psychotropen cannabinoiden zur behandlung von entzündungserkrankungen
EP2207892A4 (en) * 2007-10-15 2010-12-08 Precision Therapeutics Inc METHOD FOR SELECTION OF ACTIVE AGENTS FOR CANCER TREATMENT
US9261496B2 (en) * 2010-09-29 2016-02-16 Massachusetts Institute Of Technology Device for high throughput investigations of multi-cellular interactions
US9494573B2 (en) 2012-05-24 2016-11-15 University Of Kansas In vitro tumor in dish kit and method

Also Published As

Publication number Publication date
US20180074045A1 (en) 2018-03-15
CA2983557A1 (en) 2016-12-01
EP3304085A1 (en) 2018-04-11
IL254571A0 (en) 2017-10-31
CN108027372A (zh) 2018-05-11
JP2018517428A (ja) 2018-07-05
MX2017013035A (es) 2018-05-22
EP3954992A1 (en) 2022-02-16
EP3304085B1 (en) 2021-06-23
JP2019103508A (ja) 2019-06-27
WO2016189525A1 (en) 2016-12-01
EP3304085A4 (en) 2018-10-10
AU2016268526B2 (en) 2022-02-03
IL254571B (en) 2018-04-30
JP2021003124A (ja) 2021-01-14
AU2016268526A1 (en) 2017-10-12
HK1253861A1 (zh) 2019-07-05

Similar Documents

Publication Publication Date Title
BR112017021767A2 (pt) sistema e método para triagem de alta produtividade de células cancerosas
CN106460028B (zh) 细胞的分化状态的评价方法
BR112013018854A2 (pt) “sistema, métodos para monitoramento das condições de crescimento, rastreamento, reprodução de vegetais, crescimento aprimorado de vegetais, análise rápida de resistência ao estresse, fornecer uma população de espécimes de vegetais, determinação do efeito fenotípico, usos de um sensor de umidade capacitivo e população de espécimes de vegetais”
BR112013003391A2 (pt) biomarcadores de câncer pancreático e usos dos mesmos
RU2017101174A (ru) Набор или устройство для обнаружения рака печени и способ обнаружения
Lou et al. Comparison between two kinds of cigarette smoke condensates (CSCs) of the cytogenotoxicity and protein expression in a human B-cell lymphoblastoid cell line using CCK-8 assay, comet assay and protein microarray
BR112018073178A2 (pt) método, matriz e uso dos mesmos
WO2014186761A3 (en) Methods for determining responsiveness to an anti-cd47 agent
BRPI1008957B8 (pt) método para detecção simultânea de uma pluralidade de ácidos nucleicos alvo executado por um sistema de análise integrada em tempo real de ácidos nucleicos alvo
BR112014006432A2 (pt) biomarcadores do câncer de pulmão e seus usos
BR122018015761B8 (pt) método para confirmação de detecção e enumeração das células-alvo suspeitas em amostra de sangue compreendendo uma população de células misturadas
Xu et al. Live imaging and single-cell analysis reveal differential dynamics of autophagy and apoptosis
BR112015013403A2 (pt) métodos para sondar alvos múltiplos em uma amostra biológica, para analisar amostra biológica de multiplexação de alto rendimento e para usar um kit, série de pelo menos duas imagens que representam alvos biológicos opticamente marcados, kit para alvejar um sinal para sondar alvos múltiplos em uma amostra biológica, e, processo automatizado para alvejamento químico fotoativado de uma amostra biológica
Chen et al. Emerging biotechnology applications in natural product and synthetic pharmaceutical analyses
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
BR112016019740A2 (pt) monitoramento do estado de inflamação
WO2016187159A3 (en) Methods and compositions for target detection in a nanopore using a labelled polymer scaffold
Hartley et al. Measurement of DNA damage in individual cells using the single cell gel electrophoresis (comet) assay
BR112014032974A2 (pt) método para detecção, identificação e/ou quantificação de um ou mais carboidratos, uso de um oligotiofeno conjugado luminescente, e composto
BR112017021318A2 (pt) método implementado por computador, e mídia legível por computador
Narayan et al. Olfactory neurons obtained through nasal biopsy combined with laser-capture microdissection: a potential approach to study treatment response in mental disorders
BR112019007138A2 (pt) método e sistema de análise para testagem de uma amostra
Rusanov et al. Changes in the proteome of HaCaT keratinocytes induced by cytotoxic substance Triton X-100
EP3916104A4 (en) METHOD FOR SELECTING CELLS HIGHLY SENSITIVE TO A TARGET SUBSTANCE, AND METHOD FOR DETERMINING THE CONCENTRATION OF A TARGET SUBSTANCE HAVING AN UNKNOWN CONCENTRATION IN A SAMPLE
Douétts-Peres et al. Isolating and measuring the growth and morphology of pro-embryogenic masses in Araucaria angustifolia (Bertol.) Kuntze (Araucariaceae)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2721 DE 28-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.